| [1] |
Kuikka JT, Hiltunen J, Foged C, et al. Initial human study with single-photone emission tomography using iodine-123-labelled 3-(5-cyclopropyl-1-2-4-oxadiazo-3-yl)-7-iodo-5-6-dihydro-5-methyl-6-oxo-4H-imidazo[1, 5-a] [1, 4]-benzodiazopine[J]. Eur J Nucl Med, 1996, 23:798~803.
|
| [2] |
Leslie WD, Abrams DN, Greenberg CR, et al. Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging[J]. J Nucl Med, 1998, 37:1589~1591.
|
| [3] |
Kuikka JT, Akerman KK, Hiltunen J, et al. Striatal and extrastriatal imaging of dopamine D2 receptors in the living human brain with [125I] epidepride single-photon emission tomography[J]. Eur J Nucl Med, 1997, 24:483~487.
|
| [4] |
Langer O,Halldin C,Dolle F,et al.Carbon-11 epidepride:a suitable radioligand for PET investigation of striatal and extrastrial dopamine D2 receptors[J]. Nucl Med Biol, 1999, 28:509~518.
|
| [5] |
Pirker W, Asenbaum S, Wenger S, et al. Iodine-123-epidepride-SPECT:studies in Parkinson's disease, multiple system atrophy and Huntington's disease[J]. J Nucl Med, 1997, 38:1711~1717.
|
| [6] |
Pricker W, Riedl M,Luger A, et al. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT[J]. J Nucl Med, 1996, 37:1931~1937.
|
| [7] |
De Herder WW, Reijs AEM,de Swart J, et al. Comparison of iodine-123-epidepride and iodine-123 IBZM for dopamine D2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas[J]. Eur J Nucl Med, 1999, 26:46~50.
|